Pegvisomant interference in GH assays results in underestimation og GH levels

European Journal of Endocrinology

Volumn 156, Issue 3, 2007, Pages 315-319

  Paisley, A N ^a   Hayden, K ^b   Ellis, A ^c   Anderson, J ^a   Wieringa, G ^a   Trainer, Peter J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PEGVISOMANT;

ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG SCREENING; GROWTH HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL;

HUMAN GROWTH HORMONE; HUMANS; IMMUNOASSAY; REPRODUCIBILITY OF RESULTS;

EID: 34147156302     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02341     Document Type: Article

References (11)

1. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ & Ho KK. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. Journal of Clinical Endocrinology and Metabolism 2001 86 1716-1723.
2. Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews 2002 23 623-646.
3. Pradhananga S, Wilkinson I & Ross RJ. Pegvisomant: structure and function. Journal of Molecular Endocrinology 2002 29 11-14.
4. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Van Der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
5. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
6. Trainer PJ. Editorial: acromegaly-consensus, what consensus? Journal of Clinical Endocrinology and Metabolism 2002 87 3534-3536.
7. Van Der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RI, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
8. Van Der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA & Lamberts SW. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism 2001 86 478-481.
9. Parkinson C, Burman P, Messig M & Trainer PJ. Gender, body weight, disease activity, and prior radiotherapy influence the response to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2007 92 190-195.
10. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC & Bennett WF. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. Journal of Clinical Endocrinology and Metabolism 1999 84 2098-2103.
11. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z & Strasborger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Journal of Clinical Endocrinology and Metabolism 2001 86 3304-3310.